Metagenomi Therapeutics Inc MGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $0.73
- Day Range
- $0.72–0.72
- 52-Week Range
- $0.71–2.28
- Bid/Ask
- $0.72 / $0.80
- Shares Outstanding
- 37.78M
- Market Cap
- $27.20M
- Volume/Avg
- 278 / 151,977
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 113
- Website
- https://metagenomi.co
Valuation
Metric | MGX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.25 |
Price/Sales | 2.02 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MGX |
|---|---|
Quick Ratio | 4.37 |
Current Ratio | 4.50 |
Interest Coverage | — |
Quick Ratio
MGX
Profitability
Metric | MGX |
|---|---|
Return on Assets (Normalized) | −36.87% |
Return on Equity (Normalized) | −52.35% |
Return on Invested Capital (Normalized) | −45.10% |
Return on Assets
MGX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|k$Jxc?Z | LOCK|?%&f | $138B | |||
| Moderna Inc MRNA | LOCK|@jZ?>Y | LOCK|HZ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$@<^#tv | LOCK|#X^$ | $93B | |||
| argenx SE ADR ARGX | LOCK|QGV>#fv | LOCK|?@ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|d#@WlGq | LOCK|!F@ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|wSM@!f# | LOCK|SMV&< | $30B | |||
| Incyte Corp INCY | LOCK|Jrj#b%& | LOCK|?c | $24B | |||
| BioNTech SE ADR BNTX | LOCK|rXVhy?n | LOCK|B% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^$WYNqM | LOCK|^TY@Z | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?&C%S>! | LOCK|&?h | $15B |
United States